Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Genomic Biomarkers

Yannick Marie's Biography



Yannick Marie, Platform Manager, Universite Pierre et Marie Curie

Yannick MARIE is the manager of the genotyping and sequencing platform at the ICM foundation (Institute of the brain and spinal cord), and in the neuro-oncology team led by Pr. Delattre (Hopital Pitie Salpetriere, PARIS). After one year of work on remyelination and 3 years on complex lipids, Yannick Marie joined the team of Experimental Neuro-Oncology. During the last 15 years, he has studied and has developed new approaches to study brain tumors. He has participated in the validation of certain determinant markers in brain tumor pathology (INA, IDH1…), and in the use of new technological tools for improving both diagnosis and monitoring of this disease (COLD PCR, Digital PCR, work on FFPE samples…). With the creation of the ICM foundation, Yannick MARIE now supports the platform of molecular biology, with larger addressed topics (neurosciences) and the availability of the most Powerful technologies. In the recent years, his work has been refocused on the identification of biomarkers for diagnosis and monitoring of diseases affecting the central and peripheral nervous systems.

Yannick Marie Image

Genotyping Assay in Digital PCR Conditions for the Detection of IDH1 Mutation in Plasma

Thursday, 19 April 2012 at 14:15

Add to Calendar ▼2012-04-19 14:15:002012-04-19 15:15:00Europe/LondonGenotyping Assay in Digital PCR Conditions for the Detection of IDH1 Mutation in PlasmaSELECTBIOenquiries@selectbiosciences.com

The use of circulating tumor DNA as a biomarker is a challenge, particularly in regards to brain tumors. Through the use of COLD PCR and digital PCR, we were able not only to highlight the presence of circulating tumor DNA in patients with gliomas, but also  to validate the presence of the most frequent mutation in this disease. The strong prognostic impact of this change now allows us to propose an alternative technique for imaging in terms of diagnostics, but also for the prognosis of these tumors.


Add to Calendar ▼2012-04-19 00:00:002012-04-20 00:00:00Europe/LondonGenomic BiomarkersSELECTBIOenquiries@selectbiosciences.com